Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-2019) [0.03%]
西班牙新诊断HIV感染者的关怀质量改善（2004-2019年）
Belén Alejos,Cristina Díez,María J Galindo et al.
Belén Alejos et al.
Background: We monitored the quality of care for newly diagnosed people with HIV (PWH) in Spain, including linkage to care within 1 month of HIV diagnosis (LC-1Mo) and viral suppression within 3 months of HIV diagnosis (V...
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV [0.03%]
整合酶抑制剂相关机体组成差异很大程度上可由社会经济地位解释——针对慢性HIV感染男性患者的调查研究
Julie K Wisch,Sarah A Cooley,Kevin E Yarasheski et al.
Julie K Wisch et al.
Background: Substantial body composition alterations have been reported after starting combined antiretroviral therapy (cART). We characterized a cohort of chronically infected and virologically suppressed (VL < 50 copies...
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B [0.03%]
JNJ-73763989 的药代动力学和安全性：在健康日本成人和非日本成人中针对乙型肝炎病毒的肝脏定向 siRNA，以及与 JNJ-56136379 和核苷[酸]类似物联用治疗慢性乙型肝炎患者的疗效
Ed Gane,Man-Fung Yuen,Thomas N Kakuda et al.
Ed Gane et al.
Background: JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924. JNJ-73763989 pharmacokinetics, safety and t...
Randomized Controlled Trial
Antiviral therapy. 2022 Jun;27(3):13596535221093856. DOI:10.1177/13596535221093856 2022
Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey [0.03%]
卢旺达接受一线抗逆转录病毒治疗的成人获得性人类免疫缺陷病毒药物耐药性横断面全国代表性调查
Gentille Musengimana,Elysee Tuyishime,Athanase Kiromera et al.
Gentille Musengimana et al.
Background: We assessed the prevalence of acquired HIV drug resistance (HIVDR) and associated factors among patients receiving first-line antiretroviral therapy (ART) in Rwanda. ...
Rebecca Roediger,Elizabeth Kula Smyth,Douglas Dieterich
Rebecca Roediger
Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B. Prior to adefovir, Hepatitis B treatment was limited to two therapeutic modalities, either interferon, which carried s...
Uli Schmitz,Swami Swaminathan
Uli Schmitz
John Martin's untimely death in March 2021 was a huge loss for us personally, Gilead Sciences, the company he built over 30 years and the scientific community concerned with antiviral therapies. We wish to honor John's legacy by retelling t...
Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis [0.03%]
灯塔计划——支持国家、区域和全球层面的决策以消除病毒性肝炎
Homie Razavi
Homie Razavi
Background: Tools to eliminate Hepatitis B and C have been available and in 2016, the World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis. However, the adoption of hepatitis elimination programs has remained...
William A Lee,Andrew K Cheng
William A Lee
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that repl...
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis [0.03%]
应用替诺福韦基药物开展预防以推进艾滋病防控工作
Salim S Abdool Karim,Cheryl Baxter,Quarraisha Abdool Karim
Salim S Abdool Karim
Tenofovir-based pre-exposure prophylaxis (PrEP) revolutionized the global HIV prevention landscape. Prior to the proof-of concept trial in 2010, which demonstrated that tenofovir (TFV) could prevent sexual transmission of HIV, prevention op...
The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B [0.03%]
富马酸替诺福韦二吡美司在预防乙肝垂直传播中的作用
Calvin Q Pan
Calvin Q Pan
Background: Since immunoprophylaxis failure can occur if maternal serum hepatitis B virus (HBV) DNA levels are >200,000 IU/ml, tenofovir disoproxil fumarate (TDF) therapy has been investigated for preventing mother to chi...